PharmaEngine, Inc. 4162

TPEX · Taiwan · Health Technology

TWD 55.40+0.10 (+0.18%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

PharmaEngine, Inc. 4162

TPEX · Taiwan · Health Technology

TWD 55.40+0.10 (+0.18%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-6.10% · 6MFull-screen chart

Open TWD 55.50High TWD 55.60Low TWD 55.10Close TWD 55.40Volume 106.24K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 55.30
Day range: TWD 55.10 – TWD 55.60
52-week range: TWD 53.00 – TWD 74.40
Volume: 106.24K
Market cap: TWD 7.82B
P/E (TTM): 14.8
Dividend yield (annualized): 3.60%
Next earnings date: 2026-11-11
Avg. volume (1Y): 528.79K

Performance

1 week

0.00%

1 month

-3.99%

3 months

-9.99%

6 months

-2.15%

Year to date

-20.38%

1 year

-14.82%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Taiwan
Exchange: TPEX
Shares outstanding: 141.68M
Employees: 45
ISIN: TW0004162003
Beta: 0.21

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMay 04, 2026

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic leth

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.